Tekni-Plex Europe plans to acquire Gallazzi's Italian-based businesses

Tekni-Plex Europe NV is announcing today that its plan to acquire Gallazzi's Italian-based pharmaceutical blister film (Tradate, Varese, Lombardia) and adhesive tape substrate film (Gallarate, Varese, Lombardia) businesses has been approved by the Italian authorities supervising the sale.

The acquisition is expected to close in the second quarter of 2015. Gallazzi's Minerbio, Italy and Saint-Maur-des-Fosses, France locations are not part of the sale.

Gallazzi's Tradate site manufactures high-quality polyvinyl chloride (PVC) film and polyvinylidene chloride- (PVDC) coated barrier films for pharmaceutical blister applications in an ISO8 Cleanroom. The Tradate facility also produces PVC films for food packaging and technical PVC films and sheets. Gallazzi's Gallarate location produces thin PVC films used for adhesive-tape substrates.

"Gallazzi's manufacturing capabilities and product offerings are an excellent complement to our global Tekni-Films business," said Paul Young, Chief Executive Officer of Tekni-Plex. "The acquisition will add mono-PVC calendaring capabilities to our blister portfolio in Europe, as well as state-of-the-art PVDC coating which will strengthen our barrier blister technology base. These new capabilities will provide our customers with high-quality, innovative films and sheets to support their business needs."

Source:

Tekni-Plex, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FORT-2 trial shows promising results for bladder cancer immunotherapy combination